Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden

BJU International

Volumn 85, Issue 9, 2000, Pages 1078-1084

  Hugosson, J ^a   Aus, G ^a   Becker, C ^b   Carlsson, S ^c   Eriksson, H ^a   Lilja, H ^b   Lodding, P ^a   Tibblin, G ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Diagnosis; Epidemiology; Mortality; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SERUM; SWEDEN; SYMPTOM;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SWEDEN;

EID: 0034113162     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00679.x     Document Type: Article

References (28)

1. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for cancer-related check-up: prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42-6
2. Hugosson J, Aus G, Norlén L. Surveillance is not viable and appropriate treatment option in the management of localized carcinoma of the prostate. Urol Clin North Am 1996; 23: 557-73
3. Aus G, Hugosson J, Norlén L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995; 154: 466-9
4. Otnes B, Harvei S, Fosså SD. The burden of prostate cancer from diagnosis until death. Br J Urol 1995; 76: 587-94
5. Carlsson P, Hjertberg H, Jönsson B, Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 1989; 23: 93
6. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results ofthe Medical Research Council trial. Br J Urol 1997; 79: 235-46
7. Catalona WJ, Smith DS, Ratliff TL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156
8. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vesella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-5
9. Garnick MB. Prostate cancer: screening, diagnosis and management. Ann Intern Med 1993; 118: 804-18
10. Kramer B, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914-23
11. Adami HO, Baron JA, Rohman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958-60
12. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270: 948-54
13. Tibblin G, Adlerberth A, Lindstedt G, Björntorp P. The pituitary-gonadal axis and health in elderly men. A Study of men born in 1913. Diabetes 1996; 45: 1605-9
14. Hugosson J. European randomized study for prostatic cancer: Results of PSA related screening in Göteborg. In Schröder FH, ed. Recent Advances in Prostate Cancer and BPH. New York, London: Parthenon Publishing Group 1997: 179-84
15. Schröder FH, Hermanek P, Denis L. The TNM Classification of prostate cancer. Prostate 1992; 4 (Suppl 4): 129
16. Piironen T, Pettersson K, Suonpää M et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alfa 1-antichymotrypsin in blood samples. Urology 1996; 48: 81-7
17. Tibblin G, Welin L, Bergström R, Ronquist G, Norlén B-J, Adami H-O. The value of prostate specific antigen in early diagnosis of prostate cancer: The study of men born in 1913. J Urol 1995; 154: 1386-9
18. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94
19. Stenman UH. Serum concentrations of prostate specific antigen and its complex before diagnosis of prostate cancer. Lancet 1994; 344: 1594-8
20. Bangma CH, Kranse R, Blijemberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 773-8
21. Lodding P, Aus G, Bergdahl S et al. Characteristics of prostate cancer detected at prostate-specific antigen (PSA)-guided population based screening in males aged 50-66 years and with PSA within the interval 3-4 ng/ml. J Urol 1998; 159: 899-903
22. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterisation of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155: 816-20
23. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI. Tumour volume and prostate specific antigen: Implications for early detection and defining a window ofcurability. J Urol 1995; 154: 1808-12
24. Editorial. Lancet 1997; 349: 443
25. Labrie F, Candas B, Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212-7
26. Aus G. Hugosson J. Norlén L. Long-term survival and mortality in prostate cancer treated with non-curative intent. J Urol 1995; 154: 460-5
27. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31
28. Zincke H, Oesterling JE, Blute ML, Bergstrahl EJ, Myeres RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-7